Search Results - "Lowe, Robert S"

Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia by Kusters, D. Meeike, MD, Caceres, Maria, MS, Coll, Mauricio, MD, Cuffie, Cynthia, MD, Gagné, Claude, MD, Jacobson, Marc S., MD, FAHA, Kwiterovich, Peter O., MD, Lee, Raymond, BS, Lowe, Robert S., PhD, Massaad, Rachid, MS, McCrindle, Brian W., MD, MPH, Musliner, Thomas A., MD, Triscari, Joseph, PhD, Kastelein, John J.P., MD, PhD

“…Objectives To evaluate the lipid-altering efficacy and safety of ezetimibe monotherapy in young children with heterozygous familial hypercholesterolemia (HeFH)…”
Get full text

Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia by Bays, Harold E., MD, Averna, Maurizio, MD, Majul, Claudio, MD, Muller-Wieland, Dirk, MD, De Pellegrin, Annamaria, MD, Giezek, Hilde, MSc, Lee, Raymond, BS, Lowe, Robert S., PhD, Brudi, Philippe, MD, Triscari, Joseph, PhD, Farnier, Michel, MD, PhD

“…Hypercholesterolemic patients (n = 1,547) at high atherosclerotic cardiovascular disease risk with low-density lipoprotein cholesterol (LDL-C) levels ≥100 and…”
Get full text

Safety and Efficacy of Ezetimibe Added on to Rosuvastatin 5 or 10 mg Versus Up-Titration of Rosuvastatin in Patients With Hypercholesterolemia (the ACTE Study) by Bays, Harold E., MD, FACP, FACE, FNLA, Davidson, Michael H., MD, FACC, FNLA, Massaad, Rachid, MSc, Flaim, Doreen, MS, Lowe, Robert S., PhD, Tershakovec, Andrew M., MD, MPH, Jones-Burton, Charlotte, MD, MS

“…The present multicenter, 6-week, randomized, double-blind, parallel-group, clinical trial evaluated the safety and efficacy of ezetimibe (10 mg) added to…”
Get full text

Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin by Lakoski, Susan G, Xu, Fang, Vega, Gloria L, Grundy, Scott M, Chandalia, Manisha, Lam, Chun, Lowe, Robert S, Stepanavage, Michael E, Musliner, Thomas A, Cohen, Jonathan C, Hobbs, Helen H

“…Context: The level and duration of exposure to circulating low-density lipoprotein-cholesterol (LDL-C) are major contributors to coronary atherosclerosis…”
Get full text

Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients by Thongtang, Nuntakorn, Lin, Jianxin, Schaefer, Ernst J, Lowe, Robert S, Tomassini, Joanne E, Shah, Arvind K, Tershakovec, Andrew M

“…Abstract Objective Statins inhibit cholesterol synthesis but can upregulate cholesterol absorption, with higher doses producing larger effects. Ezetimibe…”
Get full text

Effects of ezetimibe on atherosclerosis in preclinical models by Davis, Harry R, Lowe, Robert S, Neff, David R

“…Abstract Ezetimibe (Zetia® , Ezetrol® , Merck, Whitehouse Station, NJ) is a potent inhibitor of sterol absorption, which selectively blocks the uptake of…”
Get full text

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease by Conard, Scott E., MD, Bays, Harold E., MD, Leiter, Lawrence A., MD, Bird, Steven R., MS, Rubino, Joseph, MBA, Lowe, Robert S., PhD, Tomassini, Joanne E., PhD, Tershakovec, Andrew M., MD

“…The aim of this study was to evaluate the efficacy and safety of ezetimibe 10 mg added to atorvastatin 20 mg compared with doubling atorvastatin to 40 mg in…”
Get full text

Safety and Efficacy of Ezetimibe / Simvastatin Combination Versus Atorvastatin Alone in Adults ≥65 Years of Age With Hypercholesterolemia and With or at Moderately High/High Risk for Coronary Heart Disease (the VYTELD Study) by Foody, JoAnne M., MD, Brown, W. Virgil, MD, Zieve, Franklin, MD, PhD, Adewale, Adeniyi J., PhD, Flaim, Doreen, MS, Lowe, Robert S., PhD, Jones-Burton, Charlotte, MD, MS, Tershakovec, Andrew M., MD, MPH

“…Higher than 80% of coronary heart disease-related mortality occurs in patients ≥65 years of age. Guidelines recommend low-density lipoprotein (LDL) cholesterol…”
Get full text

Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease by Bays, Harold E, Conard, Scott E, Leiter, Lawrence A, Bird, Steven R, Lowe, Robert S, Tershakovec, Andrew M

“…Abstract Background Age, gender, and race are factors that influence atherosclerotic coronary heart disease (CHD) risk and may conceivably affect the efficacy…”
Get full text

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials by Morrone, Doralisa, Weintraub, William S, Toth, Peter P, Hanson, Mary E, Lowe, Robert S, Lin, Jianxin, Shah, Arvind K, Tershakovec, Andrew M

“…Abstract Objective Patients with dyslipoproteinemia constitute the largest risk group for development of atherosclerosis and cardiovascular disease (CVD)…”
Get full text

Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome by Robinson, Jennifer G., MD, MPH, Ballantyne, Christie M., MD, Hsueh, Willa A., MD, Rosen, Jeffrey B., MD, Lin, Jianxin, MS, Shah, Arvind K., PhD, Tomassini, Joanne E., PhD, Lowe, Robert S., PhD, Tershakovec, Andrew M., MD, MPH

“…Background Treatment response to lipid-lowering therapy can vary in patients with the metabolic syndrome (MetS) due to various patient demographic and baseline…”
Get full text

Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study) by Robinson, Jennifer G., MD, MPH, Ballantyne, Christie M., MD, Hsueh, Willa, MD, Rosen, Jeffrey, MD, Lin, Jianxin, MS, Shah, Arvind, PhD, Lowe, Robert S., PhD, Hanson, Mary E., PhD, Tershakovec, Andrew M., MD, MPH

“…Background Metabolic syndrome (MetS) and atherosclerotic vascular disease (AVD) are associated with increased coronary heart disease risk. Objective To assess…”
Get full text

Infectious Virions Produced from a Human Papillomavirus Type 18/16 Genomic DNA Chimera by Meyers, Craig, Bromberg-White, Jennifer L, Zhang, Jiaping, Kaupas, Michelle E, Bryan, Janine T, Lowe, Robert S, Jansen, Kathrin U

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk by Rosen, Jeffrey B, Ballantyne, Christie M, Hsueh, Willa A, Lin, Jianxin, Shah, Arvind K, Lowe, Robert S, Tershakovec, Andrew M

“…Metabolic syndrome (MetS) and insulin resistance (IR) are increasing in prevalence, are associated with higher risk for coronary heart disease (CHD), and may…”
Get full text

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects by Chen, Xia, Kosoglou, Teddy, Statkevich, Paul, Kumar, Bharath, Li, Jing, Dockendorf, Marissa F, Wang, Guoqin, Lowe, Robert S, Jiang, Ji, Liu, Hongzhong, Wang, Zaiqi, Cutler, David L, Hu, Pei

“…Vorapaxar is a proteaseactivated receptor (PAR)-1 antagonist being developed for the prevention and treatment of thrombotic vascular events. To evaluate…”
Get full text

Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years by Constance, Christian, Ben-Yehuda, Ori, Wenger, Nanette K, Zieve, Franklin, Lin, Jianxin, Hanson, Mary E, Lowe, Robert S, Tershakovec, Andrew M

“…Few clinical studies have focused on the efficacy of lipid-lowering therapies in patients ≥65 years. After stabilization on atorvastatin 10 mg,…”
Get full text

Ezetimibe & Atorvastatin Coadministration vs Atorvastatin Uptitration or Switching to Rosuvastatin in Primary Hypercholesterolemic Patients at High Cardiovascular Risk by Bays, Harold E., MD, Averna, Maurizio, MD, Majul, Claudio, MD, Muller-Wieland, Dirk, MD, De Pellegrin, Annamaria, MD, Giezek, Hilde, MSc, Lee, Raymond, BS, Lowe, Robert S., PhD, Brudi, Philippe, MD, Triscari, Joseph, PhD, Farnier, Michel, MD

Get full text

Association of Statin Potency with Markers of Cholesterol Absorption/Synthesis and LDL-C Lowering Efficacy of Ezetimibe Add-on Therapy by Schaefer, Ernst J., MD, Thongtang, Nuntakorn, MD, Lin, Jianxin, MS, Lowe, Robert S., PhD, Tomassini, Joanne E., PhD, Shah, Arvind K., PhD, Tershakovec, Andrew M., MD, MPH

Get full text

Age, Abdominal Obesity, and Baseline High-Sensitivity C-Reactive Protein Are Associated with Low-Density Lipoprotein Cholesterol, non–High-Density Lipoprotein Cholesterol, and ApoB Responses to Lipid-Lowering Therapy in Patients with Metabolic Syndrome and Moderately High/High Coronary Heart Disease Risk by Robinson, Jennifer G., MD, Ballantyne, Christie M., MD, Hsueh, Willa A., MD, Rosen, Jeffery B., MD, Lin, Jianxin, MS, Shah, Arvind K., PhD, Tomassini, Joanne E., PhD, Lowe, Robert S., PhD, Tershakovec, Andrew M., MD, MPH

Get full text

Human Papillomavirus Type 11 (HPV-11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-like Particles Expressed in Yeast by Lowe, Robert S., Brown, Darron R., Bryan, Janine T., Cook, James C., George, Hugh A., Hofmann, Kathryn J., Hurni, William M., Joyce, Joseph G., Lehman, E. Dale, Markus, Henry Z., Neeper, Michael P., Schultz, Loren D., Shaw, Alan R., Jansen, Kathrin U.

“…It has been shown previously that immunization of animals with recombinant virus-like particles (VLPs) consisting of the viral capsid proteins L1 or L1 plus L2…”
Get full text